Click to toggle navigation menu.

NanoCept™

Antibacterial Implant Technology

60-70%

of Periprosthetic Joint Infections (PJIs) are associated with intraoperative contamination, a major clinical challenge1

Despite numerous precautions, bacterial contamination of implants remains an unsolved problem and poses a major clinical challenge, with potentially severe consequences for patients.

Joint-related infection is a significant economic burden to the healthcare system

28% of knee revision surgeries can be attributed to PJI annually.2
$1.85B is the estimated cost to the healthcare system by 2030.3
Studies have shown that PJI has been associated with lower rates of survivorship as compared to several types of cancer.3

Introducing NanoCeptTM Antibacterial Implant Technology

Mitigating the risk of bacterial contamination on implant surfaces

NanoCeptTM antibacterial technology is based on a proprietary coating that:

Mitigating the risk of bacterial contamination on implant surfaces

NanoCeptTM antibacterial technology is based on a proprietary coating that:

  • Demonstrates excellent safety and biocompatibility in preclinical in vivo and in vitro studies4

  • Delivers broad spectrum efficacy (up to 99.999% kill rate of bacteria commonly found in the OR)4,*

  • Avoids the emergence of bacterial resistance with a non-eluting, nanoscale surface4

The First Antibacterial Coating Technology shown to protect implants from bacteria at the time of surgery prior to implantation.

NanoCeptTM

Schedule a Consultation with us

The NanoCept™ coating, where applied, is intended to reduce bacterial contamination on the surface of the coated device components prior to implantation, by killing bacteria that are deposited onto the device surface from the operating environment. The device coating is not intended for the treatment of existing infections or prevention of future infections in patients. The potential clinical impact of bacterial reduction from the NanoCept™ coating, including prevention of infection or reduction of infection risk in patients, has not been evaluated in human clinical studies. CORP 1.6.25 v0.

  1. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2):302-345.
  2. Upfill-Brown, MD, et al. Epidemiology of Revision Total Knee Arthroplasty in the United States, 2012 to 2019 Arthroplasty Today volume 15, p.188-195.
  3. Premkumar A, Kolin DA, Farley KX, et al. Projected economic burden of periprosthetic joint infection of the hip and knee in the United States. J Arthroplasty 2021;36(5):1484-1489.
  4. Data on File. Onkos Surgical; 2024.

* In vitro testing.